ClinicalTrials.gg
RecruitingNCT07136922FREEDOMUpdated Sep 10, 2026

First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency

A Phase 1 interventional study of 400mg progesterone Callavid - 2hr wear and Cyclogest 400 mg in Luteal Phase Insuffiency and Progesterone Delivery, sponsored by Calla Lily Clinical Care Ltd. Recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Calla Lily Clinical Care Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The aim of this clinical trial is to assess safety of a new vaginal 400mg progesterone drug-device combination product in a first in human trial. Additionally, it aims to assess user acceptability and ability to deliver progesterone. This Phase I trial is a randomised open-label first-in-human crossover trial, recruiting participants who are non-pregnant with luteal phase insufficiency. The main questions it aims to answer are:

  1. What are the safety and tolerability profiles of the two progesterone formulations (400mg Progesterone Callavid vs. Cyclogest 400 mg), including the incidence of adverse events (if any) such as allergic reactions, gastrointestinal symptoms (e.g. bloating, constipation), and neurological effects (e.g. headache, drowsiness, euphoria)?
  2. What is usability experience for patients using the Callavid drug-device combination compared to pessaries / suppositories (i.e. Cyclogest 400 mg)?
  3. How do serum progesterone levels vary within participants when using 400 mg progesterone delivered via the Callavid drug-device combination compared to Cyclogest 400 mg, and what are the implications of this variability for dose-response relationships and future trial design?
02

Conditions studied

  • Luteal Phase Insuffiency
  • Progesterone Delivery

Keywords

  • progesterone delivery
  • progesterone
  • vaginal drug delivery
  • callavid
  • cyclogest
  • women's health
03

In context

Lead sponsor

This is the only study on the registry with Calla Lily Clinical Care Ltd as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female sex
  • Clinical diagnosis of luteal phase insufficiency on the basis of one of the following:
  • Spotting before first day of heavy menstrual bleeding
  • Short time between ovulation and menstruation
  • Symptoms of progesterone insufficiency
  • Aged 18 - 45 years
  • Experienced at least one previous miscarriage

Exclusion criteria

Exclusion Criteria:

  • Positive pregnancy test
  • Currently breastfeeding
  • Allergies or to / progesterone pessaries
  • Current or history of previous condition where hormone treatments are contraindicated e.g. breast cancer
  • Individuals who lack capacity to consent to the trial
  • Individuals who have an inability to comply with the trial procedures (e.g. cannot attend hospital for trial visits)
  • Inability to understand English
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Callavid 2-hr first, Cyclogest second, Callavid 3-hr third

    Participants are randomised to use Callavid first for 2 hour wear before crossing over to use Cyclogest. In the third round, participants receive Callavid again but for 3 hour wear.

    Combination Product: 400mg progesterone Callavid - 2hr wear · Drug: Cyclogest 400 mg · Combination Product: 400mg progesterone Callavid - 3hr wear

  • Active comparator
    Cyclogest first, Callavid 2-hr second, Callavid 3-hr third

    Participants are randomised to use Cyclogest first before crossing over to use Callavid for 2 hour wear. In the third round, participants receive Callavid again but for 3 hour wear.

    Combination Product: 400mg progesterone Callavid - 2hr wear · Drug: Cyclogest 400 mg · Combination Product: 400mg progesterone Callavid - 3hr wear

Interventions

  • Combination product400mg progesterone Callavid - 2hr wear

    400mg progesterone Callavid, 2 hour wear, twice daily for 7 days

  • Cyclogest 400 mg pessary, twice daily for 7 days

  • Combination product400mg progesterone Callavid - 3hr wear

    400mg progesterone Callavid, 3 hour wear, twice daily for 7 days

06

What researchers measure

Primary outcomes

  1. Adverse events recorded from 400 mg progesterone Callavid

    Any grade of adverse events, specifically allergy, gastrointestinal (bloating, constipation), neurological (headache, drowsiness, euphoria) according to Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: From treatment up to 24 hours after the last dose

Secondary outcomes

  1. PROMIS Anxiety questionnaire

    PROMIS short 4-item anxiety fear instrument

    Time frame: Day 1 and day 7 of treatment in each round (3 rounds total)

  2. Acceptability questionnaires

    User acceptability questionnaires on 400mg progesterone Callavid

    Time frame: Day 1 and day 7 of treatment in each round (3 rounds total)

  3. Semi-structured user experience interviews

    Semi-structured interviews with participants after completion of the crossover rounds.

    Time frame: day 7

  4. Delivery of vaginal progesterone into the blood at 2 hour and 3 hour wear

    The serum progesterone levels at time 0, 3- and 6-hour after the first dose on day 1 and the thirteenth dose which is on day 7 each round of treatment are measured. Progesterone levels are measured for both 400 mg progesterone Callavid and 400 mg Cyclogest.

    Time frame: Multiple time points on Day 1 and Day 7 of each treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Requests for anonymised participant data should be directed to the Sponsor at clinicaltrials@callali.ly. All requests will be considered by Institution Governance and a data sharing agreement might be required.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Aug 22, 2025
StartActual
Apr 20, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07136922
Lead sponsor
Calla Lily Clinical Care Ltd
Collaborators
University Hospitals Coventry and Warwickshire NHS Trust, University of Warwick
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Apr 20, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Siobhan Quenby
Contact
s.quenby@warwick.ac.uk
+442476964000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Utrogestan

Start the discussion